Search
Gain Therapeutics Inc
GANXAdd to Watchlist
1.170USD
+0.020+1.74%
Close 10-27 16:00（ET）
51.06MMarket Cap
LossP/E TTM
Gain Therapeutics Inc (GANX) Stock Price Target & Forecast
Analyst Rating
Based on 5 analysts giving stock ratings to Gain Therapeutics Inc in the past month.
Buy
2 Strong Buy
3 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
7.250USD+530.43%
GANX Analyst Recommendation Trends
In the current month, GANX has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. GANX average Analyst price target in the last month is 7.250.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
5
5
5
5
5
5
GANX Analyst Rating for Peer Comparison
Updated: Oct 27, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
Biontech SE
BNTX
4
12
8
0
0
24
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Cytokinetics Inc
CYTK
5
16
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Financial Forecasting
Based on analysts' estimates, GANX EPS is projected to reach -0.128 in FY2026Q3, following reported EPS of -0.109 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.14
-0.14
-0.14
-0.13
-0.13
Actual
-0.12
-0.13
-0.11
--
--
Surprise
+17.26%
+3.41%
+23.21%
--
--
FAQs
What is Gain Therapeutics Inc's price target?
Analysts forecast that Gain Therapeutics Inc's price target is USD 7.25, with the highest forecast at USD 8.00 and the lowest forecast at USD 5.00.
How have Gain Therapeutics IncGANX's recent earnings per share performed?
The market expectation was USD -0.11, while Gain Therapeutics IncGANX's earnings per share (EPS) for the previous quarter was USD -0.13. EPS for the next quarter is expected at USD -0.13.
What is the analyst rating for Gain Therapeutics Inc?
Based on the ratings of Gain Therapeutics Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.